Shattuck Labs, Inc.
STTK · Pharmaceutical Preparations · 76.7M shares · +35%/yr ↑ dilution · EDGAR filings ↗
Reference price $4.00 · est. market cap ~$307M — last insider purchase, 2026-06-09 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)
Grade
D44Clinical/early-stage biotech — immuno-oncology clinical, well-funded.
Strengths
- Liquidity — current ratio 11.7 (83rd)
Risks
- Pre-revenue, deep losses — per metrics
- Pre-revenue/clinical-stage — history of losses & need for capital per risk factors
- Binary clinical & funding risk — per 10-K
Notable findings
- Chronic dilutionShare count +35%/yr over 4y (dilution, book value/share -91%)
- Net lossNet loss (net margin -4880.9%)
- Cash burnNegative free cash flow (-40.0M)
- Fund exitedNotable fund(s) exited this quarter: VANGUARD GROUP INC
- Exec changeRecent 8-K item 5.02 8-K ↗
- Insider buyingInsider buying — 1 open-market buy(s) by 1 insider(s) (~$250,000, last 6mo) Form 4 ↗
- Trial resultTrial topline data reported — see 8-K for outcome 8-K ↗
- Insider sellingInsider selling — 2 open-market sale(s) by 2 insider(s) (cluster of 2 insiders, last 6mo) Form 4 ↗
- Revenue declineRevenue -82.5% YoY
- Notable holderHeld by 5 notable fund(s): RENAISSANCE TECHNOLOGIES LLC, FMR LLC, STATE STREET CORP +2 more (as of 2026-03-31)
Quarterly revenue
Last 4 quarters · from SEC filings.
Key metrics
Operating margin
-5150.8%
Net margin
-4880.9%
Return on equity
-59.2%
Return on assets
-53.6%
Revenue growth (QoQ)
-82.5%
Current ratio
11.7×
Free cash flow
-$40M
EBITDA
-$48M
Tangible book value
$82M
Cash & investments
$78M
Cash runway
8q
Stock comp / revenue
699.5%
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-06-09 | SIEGALL CLAY B | Buy | 62K | $4.00 |
| 2026-05-22 | SIEGALL CLAY B | Grant | 128K | $1.08 |
| 2026-05-21 | Shukla Abhinav A. | Grant | 5.1K | $1.08 |
| 2026-05-15 | Stout Stephen | Grant | 13K | $1.08 |
| 2026-05-12 | Neill Andrew R | Grant | 64K | $1.08 |
| 2026-05-12 | Shukla Abhinav A. | Option exercise | 2.0K | $3.57 |
| 2026-05-12 | Shukla Abhinav A. | Sell | 2.0K | $7.01 |
| 2026-05-12 | Pandite Arundathy N. | Sell | 30K | $6.61 |
| 2026-05-12 | Schreiber Taylor | Grant | 26K | $1.08 |
| 2026-05-10 | Stout Stephen | Tax withheld | 968 | $6.85 |
| 2026-01-25 | Pandite Arundathy N. | Tax withheld | 3.2K | $4.15 |
| 2026-01-25 | Stout Stephen | Tax withheld | 593 | $4.15 |
| 2026-01-25 | DeYoung Casi | Tax withheld | 2.3K | $4.15 |
| 2026-01-25 | Neill Andrew R | Tax withheld | 2.6K | $4.15 |
| 2026-01-10 | Stout Stephen | Tax withheld | 4.2K | $4.75 |
| 2026-01-10 | DeYoung Casi | Tax withheld | 5.7K | $4.75 |
| 2026-01-10 | Pandite Arundathy N. | Tax withheld | 6.9K | $4.75 |
| 2026-01-10 | Neill Andrew R | Tax withheld | 6.7K | $4.75 |
| 2025-08-25 | ORBIMED ADVISORS LLC | Buy | 5.3M | $0.87 |
| 2025-08-25 | ORBIMED ADVISORS LLC | Buy | 1.1M | $0.87 |
| 2025-08-25 | Ashiya Mona | Buy | 5.3M | $0.87 |
| 2025-08-25 | Ashiya Mona | Buy | 1.1M | $0.87 |
| 2025-08-25 | Neill Andrew R | Grant | 64K | $0.87 |
| 2025-08-25 | Schreiber Taylor | Grant | 26K | $0.87 |
| 2025-08-25 | Stout Stephen | Grant | 13K | $0.87 |
| 2025-08-25 | SIEGALL CLAY B | Grant | 128K | $0.87 |
| 2025-08-25 | Shukla Abhinav A. | Grant | 5.1K | $0.87 |
| 2025-01-25 | Shukla Abhinav A. | Tax withheld | 2.3K | $1.16 |
| 2025-01-25 | DeYoung Casi | Tax withheld | 2.3K | $1.16 |
| 2025-01-25 | Pandite Arundathy N. | Tax withheld | 3.2K | $1.16 |
| 2025-01-10 | Pandite Arundathy N. | Tax withheld | 6.9K | $1.19 |
| 2025-01-10 | DeYoung Casi | Tax withheld | 5.7K | $1.19 |
| 2025-01-10 | Shukla Abhinav A. | Tax withheld | 4.8K | $1.19 |
All non-derivative Form 4 activity (SEC), newest first.
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT07158437 ↗ | Phase 1 Study of SL-325 in Healthy Volunteers Healthy Volunteers | PHASE1 | Active Not Recruiting | 2026-07-01 |
| NCT05483933 ↗ | Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer | PHASE1 | Completed | 2025-02-07 |
| NCT05275439 ↗ | Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML Acute Myeloid Leukemia, Myelodysplastic Syndromes | PHASE1 | Terminated | 2025-02-06 |
| NCT03894618 ↗ | SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas Squamous Cell Carcinoma of the Head and Neck, Melanoma | PHASE1 | Completed | 2023-05-04 |
| NCT04406623 ↗ | Phase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian Cancer Ovarian Cancer, Fallopian Tube Cancer | PHASE1 | Completed | 2023-02-02 |
| NCT04502888 ↗ | Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell Carcinoma of the Head and Neck or Skin Cutaneous Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck | PHASE1 | Terminated | 2022-04-08 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Notable events (8-K)
| Date | Items | |
|---|---|---|
| 2026-06-11 | Material agreementExhibits | filing ↗ |
| 2026-06-09 | Reg FDOtherExhibits | filing ↗ |
| 2026-06-02 | Exec/director changeShareholder voteExhibits | filing ↗ |
| 2026-05-07 | Results | filing ↗ |
| 2026-03-05 | ResultsExhibits | filing ↗ |
| 2026-02-05 | Other | filing ↗ |
| 2026-01-22 | Material agreementExhibits | filing ↗ |
| 2025-11-06 | Results | filing ↗ |
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-06-11 | 2026-06-09 | 0001193125-26-266745 ↗ |
| 8-K | 2026-06-09 | 2026-06-08 | 0001193125-26-263831 ↗ |
| 8-K | 2026-06-02 | 2026-05-28 | 0001193125-26-253784 ↗ |
| 10-Q | 2026-05-07 | 2026-03-31 | 0001628280-26-031661 ↗ |
| 8-K | 2026-05-07 | 2026-05-07 | 0001628280-26-031643 ↗ |
| 8-K | 2026-03-05 | 2026-03-05 | 0001628280-26-014987 ↗ |
| 10-K | 2026-03-05 | 2025-12-31 | 0001628280-26-014989 ↗ |
| 8-K | 2026-02-05 | 2026-02-05 | 0001193125-26-039488 ↗ |
| 8-K | 2026-01-22 | 2026-01-22 | 0001193125-26-019682 ↗ |
| 8-K | 2025-11-06 | 2025-11-06 | 0001680367-25-000056 ↗ |
| 10-Q | 2025-11-06 | 2025-09-30 | 0001680367-25-000057 ↗ |
| 8-K/A | 2025-11-06 | 2025-11-06 | 0001680367-25-000060 ↗ |